Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents
Open Access
- 14 October 2021
- Vol. 13 (20), 5141
- https://doi.org/10.3390/cancers13205141
Abstract
Richter transformation (RT) is a poorly understood complication of chronic lymphocytic leukemia (CLL) with a dismal prognosis. It is associated with a switch in histopathology and biology, generally with a transformation of the original CLL clone to diffuse large B-cell lymphoma (DLBCL) or less frequently to Hodgkin’s variant of Richter transformation (HVRT). It occurs in 2–10% of CLL patients, with an incidence rate of 0.5–1% per year, and may develop in treatment-naïve patients, although it is more common following therapy. In recent years, there has been a deeper understanding of the molecular pathogenesis of RT that involves the inactivation of the TP53 tumor suppressor gene in 50–60% of cases and the activation of aberrations of NOTCH1 and MYC pathways in about 30% of cases. Compared to the preceding CLL, 80% of cases with DLBCL-RT and 30% of HVRT harbor the same IGHV-D-J rearrangements, indicating a clonal evolution of the disease, while the remaining cases represent de novo lymphomas that are clonally unrelated. Despite advances in understanding the molecular variations and the pathogenesis of the disease, there is still no significant improvement in patient outcomes. However, if no clinical trials were designed for patients with RT in the past, now there many studies for these patients that incorporate new drugs and novel combinations that are being explored. In this review, we summarize the new information accumulated on RT with special emphasis on results involving the novel therapy tested for this entity, which represents an unmet clinical need.Keywords
This publication has 105 references indexed in Scilit:
- Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter SyndromeClinical Lymphoma Myeloma and Leukemia, 2013
- Diffuse large B‐cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patientsBritish Journal of Haematology, 2013
- Richter syndrome: a review of clinical, ocular, neurological and other manifestationsBritish Journal of Haematology, 2008
- Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndromeBritish Journal of Haematology, 2008
- Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2008
- Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemiaBritish Journal of Haematology, 2007
- Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell TransplantationJournal of Clinical Oncology, 2006
- Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter's syndromeLeukemia, 2003
- Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte‐macrophage–colony stimulating factor (GM‐CSF) alternating with methotrexate and cytarabine plus rituximab and GM‐CSF in patients with Richter syndrome or fludarabine‐refractory chronic lymphocytic leukemiaCancer, 2003
- Fractionated Cyclophosphamide, Vincristine, Liposomal Daunorubicin (Daunoxome), and Dexamethasone (HyperCVXD) Regimen in Richter's SyndromeLeukemia & Lymphoma, 2001